Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
| Just accepted | Online first | Issue | Totals | |
|---|---|---|---|---|
| HTML pages views | 0 | 0 | 36 | 36 |
| PDF downloads | 0 | 0 | 2 | 2 |
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.
|